

**Comments from Wyeth on the Appraisal Consultation Document - Bevacizumab, sorafenib,  
sunitinib and temsirolimus for the treatment of renal cell carcinoma**

<b>Section No.</b>	<b>Section Title</b>	<b>Page Reference</b>	<b>Comments</b>
3.4.1	temsirolimus	8	4 <sup>th</sup> bullet should read <u>serum</u> lactate dehydrogenase
4.1.11		15	Errors in the following data points, identified and corrected by Wyeth in response to the Assessment Report, have been transcribed into the ACD: OS data, no prior nephrectomy HR 0.61 (not 0.62), 95% CI 0.41 to 0.91 (not 0.42 to 0.93) OS data, prior nephrectomy 95% CI 0.63 to 1.11 (not 0.65 to 1.12) OS data, clear cell carcinoma 95% CI 0.64 to 1.08 (not 0.64 to 0.1.06) It is not clear whether the erroneous values were used in the PenTAG model
4.1.12		15	It is stated that no statistical analysis was reported for interim analysis PFS. However this analysis was provided to NICE at the time of our response to the Assessment Report.
4.2.6	First-line treatment...	23	Suspect title above should be 'First-line treatment for people <u>unsuitable</u> for Immunotherapy'